House Republicans led by Energy and Commerce Committee Chair Cathy McMorris Rodgers, R-OR, succeeded in pushing a bill (HR 485) through the full House along party lines 7 February that would bar using quality-adjusted life years (QALYs) or any “similar measure” as a metric in coverage and payment determinations in federal health care programs.
QALY Bill Clears House But Its Vague Ban Against ‘Similar Measures’ Unlikely To Succeed In Senate
The legislation is a ‘Trojan horse’ designed to undermine the Biden Administration’s policies on cutting drug prices, a leading Democrat claims.
More from Market Access
• By
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
• By
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.
More from Pink Sheet
• By
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
• By
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.